NEW YORK (GenomeWeb) – Contract research organization Cenix BioScience this week announced a research framework agreement with metabolite services and biomarker firm Metanomics Health.
As the first assignment, Cenix will perform a target validation project for Metanomics for an undisclosed disease indication. Cenix will use its expertise in high-content screening based on the Definiens XD image analysis platform for the comprehensive functional characterization of target genes designated by Metanomics, it said.
Financial and other terms of the deal were not disclosed.
Cenix has operations in Germany and the US and specializes in genome-scale gene modulation studies and high-throughput, high-content pharmacology. Metanomics, a BASF Group company based in Germany, provides metabolite profiling services and develops metabolomic biomarkers.